Abstracts Archive - Page 1103 of 2607 - ACR Meeting Abstracts

Abstract Number: 2444 • 2019 ACR/ARP Annual Meeting
Real-world Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Biologic Therapies
Jessica Walsh¹, Qian Cai ², Timothy Fitzgerald ³, Christopher Pericone ², Pankaj Shukla ⁴ and Soumya Chakravarty ⁵, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Mu-Sigma, Chicago, IL, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA
Background/Purpose: Though biologic therapies have demonstrated long-term response in randomized clinical trials for psoriatic arthritis (PsA), such patient populations and settings may not reflect the…
Abstract Number: 2445 • 2019 ACR/ARP Annual Meeting
Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity
Jessica Walsh¹, Alexis Ogdie ², Kaleb Michaud ³, Steve Peterson ⁴, Elizabeth Holdsworth ⁵, Chetan Karyekar ⁴, Nicola Booth ⁶, Jessalyn Kemp ⁷, Soumya Chakravarty ⁸, Shelly Kafka ⁹ and Laure Gossec ¹⁰, ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Janssen Global Services, LLC, Horsham, PA, ⁵Adelphi Real World, Manchester, England, United Kingdom, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Adelphi Real World, Manchester, United Kingdom, ⁸Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁹Janssen Scientific Affairs, LLC, Horsham, PA, ¹⁰Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: PsA is a chronic, inflammatory disease characterised by peripheral arthritis, axial disease, dactylitis, enthesitis and skin and nail psoriasis. The impact of skin and…
Abstract Number: 2446 • 2019 ACR/ARP Annual Meeting
Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
Elsa Vieira-Sousa¹, Mónica Eusébio ², Pedro Ávila-Ribeiro ³, Nikita Khmelinskii ⁴, Rita Cruz-Machado ⁵, Teresa Martins Rocha ⁶, Miguel Bernardes ⁷, Daniela Santos-Faria ⁸, Joana Leite Silva ⁸, Helena Santos ⁹, Cláudia Miguel ¹⁰, Pedro Carvalho ¹¹, Tiago Costa ¹², Lídia Teixeira ¹³, Tiago Meirinhos ¹⁴, Patrícia Nero ¹⁵, João Eurico Fonseca ³ and Maria José Santos ¹⁶, ¹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²Portuguese Society of Rheumatology, Lisbon, Portugal, ³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ⁴Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Lisbon, Portugal., Lisbon, Portugal, ⁵Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHULN; Lisboa, Portugal. Centro Académico de Medicina de Lisboa, Portugal., Lisbon, Portugal, ⁶Rheumatology Department, Porto, Porto, Portugal, ⁷Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ⁸Rheumatology Department, ULSAM, Ponte de Lima, Portugal, ⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Rheumatology Department, CHUC and CHUA, Faro, Portugal, ¹²Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ¹³Rheumatology Department, HGO, Almada, Portugal, ¹⁴Rheumatology Department, CHBV, Aveiro, Portugal, ¹⁵Hospital CUF Descobertas, Lisbon, Portugal, ¹⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal
Background/Purpose: The impact of gender on tumor necrosis factor inhibitors (TNFi) effectiveness has been poorly studied in Psoriatic Arthritis (PsA) patients. The objective of this…
Abstract Number: 2447 • 2019 ACR/ARP Annual Meeting
Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment
Michaela Koehm¹, Sarah Ohrndorf ², Tanja Rossmanith ³, Hans-Eckhard Langer ⁴, Marina Backhaus ⁵, Gerd Burmester ⁶, Siegfried Wassenberg ⁷, Benjamin Köhler ⁸, Harald Burkhardt ¹ and Frank Behrens ¹, ¹Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Fraunhofer IME-TMP, Frankfurt, Germany, ⁴RHIO, Düsseldorf, Germany, ⁵Park-Klinik Weissensee, Berlin, Germany, ⁶Charité—University Medicine Berlin, Berlin, Germany, ⁷Centre of Rheumatology, Ratingen, Germany, ⁸Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…
Abstract Number: 2448 • 2019 ACR/ARP Annual Meeting
Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission
Marie Moly¹, Cédric Lukas ², Jacques Morel ¹, Bernard Combe ³ and Gaël Mouterde ⁴, ¹CHU Montpellier, Montpellier, France, ²Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴CHU Montpellier and Univ Montpellier, Montpellier, France
Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) requires evaluation of multiple aspects and can be difficult. Perception of disease activity by patient and…
Abstract Number: 2449 • 2019 ACR/ARP Annual Meeting
Assessing Risk of PsA Progression: Results from a Combined Psoriasis-PsA Center Cohort
Rebecca Haberman¹, Samrachana Adhikari ¹, Deborah Ramirez ², Eileen Lydon ¹, Malavika Attur ¹, Bruno Lovisi ², Soumya Reddy ¹, Andrea Neimann ¹, Andrea Troxel ¹ and Jose Scher ³, ¹NYU School of Medicine, New York City, ²NYU School of Medicine, New York, ³New York University School of Medicine, New York, NY
Background/Purpose: About 30% of patients with skin psoriasis (PsO) develop psoriatic arthritis (PsA). The reasons for why only some progress to synovio-enthesial disease from skin…
Abstract Number: 2450 • 2019 ACR/ARP Annual Meeting
The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center
Rebecca Haberman¹, Samrachana Adhikari ¹, Deborah Ramirez ², Eileen Lydon ¹, Malavika Attur ¹, Andrea Neimann ¹, Soumya Reddy ¹, Andrea Troxel ¹ and Jose Scher ³, ¹NYU School of Medicine, New York City, ²NYU School of Medicine, New York, ³New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease affecting skin, joints, and other domains. While psychiatric diseases (i.e., depression and anxiety) are known comorbidities,…
Abstract Number: 2451 • 2019 ACR/ARP Annual Meeting
Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Rebecca Persson¹, Katrina Wilcox Hagberg ¹, Ellen Qian ¹, Catherine Vasilakis-Scaramozza ¹, Steve Niemcryk ², Michael Peng ², Maria Paris ², Anders Lindholm ² and Susan Jick ³, ¹Boston Collaborative Drug Surveillance Program, Lexington, ²Celgene Corporation, Summit, ³Boston Collaborative Drug Surveillance Program and Boston University School of Public Health, Boston
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for cardiovascular (CV) events, but different treatment options may not have the same rates of…
Abstract Number: 2452 • 2019 ACR/ARP Annual Meeting
The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients
Lihi Eder¹, Quan Li ², Dana Jerome ³, Chandra Farrer ⁴, Proton Rahman ⁵ and Tanya N. Burry ⁶, ¹Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, ³University of Toronto, Toronto, ⁴University of Toronto, Toronto, Canada, ⁵Memorial University, Newfoundland, NL, Canada, ⁶Memorial University, St. Johns, Canada
Background/Purpose: Improved understanding of the complex genetic architecture of PsA along with the reduction in the cost of genetic testing provide an opportunity to assess…
Abstract Number: 2453 • 2019 ACR/ARP Annual Meeting
Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis
Ana-Maria Orbai¹, Jamie Perin ², Albert W Wu ³, Katherine C. Smith ⁴ and Clifton Bingham ⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Public Health, Department of International Health, Baltimore, ³Johns Hopkins University Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, ⁴Johns Hopkins University Bloomberg School of Public Health, Department of Health, Behavior and Society, Baltimore, MD, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: Pain, physical function and fatigue are outcomes reported as having the greatest importance to people with psoriatic arthritis (PsA)1,2. We assessed these outcomes in…
Abstract Number: 2454 • 2019 ACR/ARP Annual Meeting
PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Ana-Maria Orbai¹, Rebecca Manno ², Jamie Perin ³, Noori Kim ⁴, Katherine C. Smith ⁵, Albert W Wu ⁶, Clifton Bingham ⁷ and Uzma Haque ², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ³Johns Hopkins University School of Public Health, Department of International Health, Baltimore, ⁴Johns Hopkins University School of Medicine, Department of Dermatology, Baltimore, MD, ⁵Johns Hopkins University Bloomberg School of Public Health, Department of Health, Behavior and Society, Baltimore, MD, ⁶Johns Hopkins University Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD
Background/Purpose: Psoriatic arthritis (PsA) symptoms and quality of life are core domains for PsA assessment1. The PROMIS Profile29 measures symptoms and quality of life using…
Abstract Number: 2455 • 2019 ACR/ARP Annual Meeting
Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
Ana-Maria Orbai¹, Birt Julie ², Elizabeth Holdsworth ³, Nicola Booth ⁴, Matthew M. Hufford ², Malatestinic William ², Aubrey Trevelin Sprabery ² and Anthony Reginato ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Division of Rheumatology, Providence VAMC, Associate Professor in Medicine, The Warren Alpert School of Medicine, Providence
Background/Purpose: Enthesitis, a characteristic clinical feature of psoriatic arthritis (PsA) [1], is a core outcome for PsA clinical trials. While enthesitis is considered important when…
Abstract Number: 2456 • 2019 ACR/ARP Annual Meeting
Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Vinod Chandran ², Dafna Gladman ³ and Lihi Eder ⁴, ¹University of Toronto, Women's College Hospital, University Health Network, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁴Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: Valuable information on cardiovascular disease outcomes can be obtained from large cohort studies. Such studies often rely on self-reported events, which are best validated…
Abstract Number: 2457 • 2019 ACR/ARP Annual Meeting
Increased Prevalence of Systemic Lupus Erythematosus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study
Danielle Korkus ¹, Tal Gazitt ², Arnon Dov Cohen ³, Ilan Feldhamer ⁴, Idit Lavi ², Amir Haddad ², Sari Greenberg-Dotan ⁴, Erez Batat ⁴ and Devy Zisman⁵, ¹The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel, ²Carmel Hospital, Haifa, Israel, ³Central Headquarters, Clalit Health Services,Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel, Tel Aviv, Israel, ⁴Central Headquarters, Clalit Health Services, Tel Aviv, Israel, ⁵Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel
Background/Purpose: Patients with psoriasis and psoriatic arthritis (PsA) can develop a variety of comorbidities which may influence the therapeutic regimen and affect treatment results. Previous…
Abstract Number: 2458 • 2019 ACR/ARP Annual Meeting
Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation
Carina Borst¹, Farideh Alasti ² and Daniel Aletaha ³, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriatic arthritis (PsA) belongs to the group of the spondylarthropathies. It is associated with psoriasis and typically seronegative for autoantibodies. PsA disease activity can…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].